ZyVersa Financial Statements From 2010 to 2025
| ZVSA Stock | 0.61 0.01 1.61% |
Check ZyVersa Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ZyVersa Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . ZyVersa financial statements analysis is a perfect complement when working with ZyVersa Therapeutics Valuation or Volatility modules.
Check out the analysis of ZyVersa Therapeutics Correlation against competitors. ZyVersa Therapeutics Company Shares Owned By Institutions Analysis
ZyVersa Therapeutics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current ZyVersa Therapeutics Shares Owned By Institutions | 2.24 % |
Most of ZyVersa Therapeutics' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ZyVersa Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 2.24% of ZyVersa Therapeutics are shares owned by institutions. This is 94.98% lower than that of the Biotechnology sector and 95.28% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 94.29% higher than that of the company.
ZyVersa Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ZyVersa Therapeutics's current stock value. Our valuation model uses many indicators to compare ZyVersa Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ZyVersa Therapeutics competition to find correlations between indicators driving ZyVersa Therapeutics's intrinsic value. More Info.ZyVersa Therapeutics is rated fourth in return on equity category among its peers. It is rated third in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ZyVersa Therapeutics' earnings, one of the primary drivers of an investment's value.About ZyVersa Therapeutics Financial Statements
ZyVersa Therapeutics stakeholders use historical fundamental indicators, such as ZyVersa Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although ZyVersa Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in ZyVersa Therapeutics' assets and liabilities are reflected in the revenues and expenses on ZyVersa Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ZyVersa Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out the analysis of ZyVersa Therapeutics Correlation against competitors. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.